(https://safebiologics.org/)



ASBM Statement on Executive Order Implementing MFN Pricing

Statement from the Alliance for Safe Biologic Medicines (ASBM) on the Administration's Executive Order Implementing MFN Pricing

May 15, 2025

The Alliance for Safe Biologic Medicines (ASBM) opposes the Administration's May 12, 2025 Executive Order (https://www.whitehouse.gov/presidential-actions/2025/05/delivering-most-favored-nation-prescription-drug-pricing-to-american-patients/)establishing Most Favored Nation (MFN) pricing for prescription drugs.

This approach would import foreign price controls from countries where patients wait longer and have less access to the newest, most effective treatments. In nations where these policies are in place, patients face higher mortality rates from diseases like cancer and have fewer therapeutic options overall. For example:

- Of new cancer medications, 90% are available to US patients within the first year of launch, whereas less than half of these are available to cancer patients in Germany, the UK, France, and Canada within the first year.
- Many medicines are never available in these jurisdictions: Of cancer medicines launched globally

between 2011 and 2019, more than 96% are available to US patients while only 65% are available in Australia, Japan and the UK.
- Cancer death rates per 100,000 are 1.6 to 1.8 times higher in Europe than those in the US. In a country the size of the U.S., European cancer death rates would translate to an additional 400,000 dead from cancer each year.

“This misguided proposal jeopardizes American leadership in pharmaceutical innovation and patient access to cutting-edge medicine by importing European-style price controls,” says Andrew Spiegel, ASBM co-founder and Executive Director of the Global Colon Cancer Association: “Europeans come to the U.S. for quality care and access to the newest and best treatments- we don’t go there. American patients should not be asked to accept reduced access and worse outcomes because the government is chasing shortsighted savings.”

Rather than importing flawed systems that ration access to lifesaving medicines, policymakers should build on the success of market-based competition in the U.S. in lowering prices—including the growing adoption of safe, effective biosimilars leading to $36 billion in savings since their introduction while building high confidence among physicians and patients. In addition, the Administration’s recent support (https://www.whitehouse.gov/presidential-actions/2025/04/lowering-drug-prices-by-once-again-putting-americans-first/) for reforming the rebating and formulary practices of Pharmacy Benefit Managers (PBMs), widely acknowledged as contributing to the high cost of medications, presents a more promising means of controlling drug costs without reducing patient access.

ASBM urges the Administration to work with patient advocacy organizations, physicians, and other stakeholders to pursue policies that maintain America’s leadership in biopharmaceutical development and ensure patients have continued access to those medicines, rather than undermining these through misguided pricing mandates.

###

LATEST NEWS

Trust is Built on Data: Preserving the FDA’s Evidence-Based Approach to Interchangeable Biosimilars

(https://safebiologics.org/trust-is-built-on-data-preserving-the-fdas-evidence-based-approach-to-interchangeable-biosimilars/)

By Michael Reilly, Executive Director, Alliance for Safe Biologic Medicines (ASBM) In a recent CBS News interview, newly appointed FDA Commissioner Dr. Marty Makary called for more robust clinical evidence before recommending the latest COVID-19 booster shots. “There’s a void of data,” Dr. Makary said, underscoring a renewed focus on restoring public trust through a […]

Read More (https://safebiologics.org/trust-is-built-on-data-preserving-the-fdas-evidence-based-approach-to-interchangeable-biosimilars/)

Statement from the ASBM on Senate HELP Committee 340B Reform Report

(https://safebiologics.org/statement-from-asbm-on-senate-help-committee-340b-reform-report/)
April 29, 2025 The Alliance for Safe Biologic Medicines (ASBM) commends Senator Bill Cassidy and the Senate HELP Committee for their new report, “Congress Must Act to Bring Needed Reforms to the 340B Program.” The program is designed to support underserved populations by ensuring access to medicines by allowing qualifying entities to safety-net hospitals, community […]

Read More (https://safebiologics.org/statement-from-asbm-on-senate-help-committee-340b-reform-report/)

ASBM Statement on President Trump’s Executive Order Supporting Patients Who Depend on Small-Molecule Medicines

(https://safebiologics.org/asbm-statement-on-president-trumps-executive-order-supporting-patients-who-depend-on-small-molecule-medicines/)
April 21, 2025 The Alliance for Safe Biologic Medicines (ASBM) commends President Donald J. Trump for his leadership in issuing an executive order to address the harmful “pill penalty” contained within the Inflation Reduction Act (IRA). This provision, enacted during the Biden administration, imposes price controls on small-molecule medicines—commonly delivered in pill or tablet form—just […]

Read More (https://safebiologics.org/asbm-statement-on-president-trumps-executive-order-supporting-patients-who-depend-on-small-molecule-medicines/)

 (https://www.youtube.com/user/SafeBiologics?feature=watch) 

(https://www.facebook.com/pages/Alliance-for-Safe-Biologic-Medicines/119874521411015) 

(https://twitter.com/SAFEbiologics)

SafeBiologics
ALLIANCE for SAFE BIOLOGIC MEDICINES (https://safebiologics.org/)

The Alliance for Safe Biologic Medicines is an organization composed of diverse healthcare groups — from patients to physicians, medical innovators, and others who are working together to ensure patient safety is at the forefront of the biosimilars policy discussion.

Contact Us (/contact-us)

WHO WE ARE

About Us (https://safebiologics.org/about-us/)

Contact Us (https://safebiologics.org/alliance-chairman/)

Member Partners (https://safebiologics.org/member-partners/)

International Advisory Board (https://safebiologics.org/international-advisory-board/)

NEWS

Latest News (https://safebiologics.org/category/latest-news/)

Letters (https://safebiologics.org/letters/)

Newsletter (https://safebiologics.org/category/newsletter/)

Press Releases (https://safebiologics.org/category/press-releases/)

Recent Events (https://safebiologics.org/category/recent-events/)

THE ISSUE

Interchangeable Biosimilars (https://safebiologics.org/icbiosims/)

Inflation Reduction Act (IRA) (https://safebiologics.org/ira/)

Naming (https://safebiologics.org/naming/)

Substitution Policy (https://safebiologics.org/substitution-policy/)

Biologic Safety (https://safebiologics.org/biologic-safety/)

BIO Principles (https://safebiologics.org/bio-principles/)

POLICY

Australia (https://safebiologics.org/australia/)

Canada (https://safebiologics.org/canada/)

European Union (https://safebiologics.org/european-union/)

FDA (https://safebiologics.org/fda/)

FDA Guidance (https://safebiologics.org/fda-guidance/)

In the States (/states)

RESOURCES

Surveys (https://safebiologics.org/surveys/)

Courses (https://safebiologics.org/courses/)

Webinars (https://safebiologics.org/webinars/)